[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Centessa Pharmaceuticals Plc ADR (CNTA)

Centessa Pharmaceuticals Plc ADR (CNTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,907,936
  • Shares Outstanding, K 149,228
  • Annual Sales, $ 15,000 K
  • Annual Income, $ -197,530 K
  • EBIT $ -208 M
  • EBITDA $ -206 M
  • 60-Month Beta 1.13
  • Price/Sales 394.06
  • Price/Cash Flow N/A
  • Price/Book 12.13

Options Overview Details

View History
  • Implied Volatility 12.43% (-3.75%)
  • Historical Volatility 104.96%
  • IV Percentile 4%
  • IV Rank 0.94%
  • IV High 219.48% on 10/27/25
  • IV Low 10.46% on 05/05/26
  • Expected Move (DTE 4) 0.54 (1.37%)
  • Put/Call Vol Ratio 4.57
  • Today's Volume 757
  • Volume Avg (30-Day) 1,267
  • Put/Call OI Ratio 2.92
  • Today's Open Interest 44,536
  • Open Int (30-Day) 38,253
  • Expected Range 39.05 to 40.13

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.40
  • Number of Estimates 3
  • High Estimate $-0.39
  • Low Estimate $-0.41
  • Prior Year $-0.38
  • Growth Rate Est. (year over year) -5.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.16 +1.10%
on 04/13/26
39.83 -0.62%
on 05/05/26
+0.11 (+0.28%)
since 04/10/26
3-Month
23.03 +71.91%
on 02/12/26
40.26 -1.66%
on 03/31/26
+16.03 (+68.04%)
since 02/11/26
52-Week
10.95 +261.55%
on 06/05/25
40.26 -1.66%
on 03/31/26
+27.29 (+221.87%)
since 05/09/25

Most Recent Stories

More News
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--CLBK, NFBK, AFBI, and CNTA

NEW YORK , May 11, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders...

AFBI : 22.48 (+0.09%)
NFBK : 13.92 (-0.85%)
CNTA : 39.59 (unch)
CLBK : 19.44 (-0.36%)
Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Centessa Pharmaceuticals...

CNTA : 39.59 (unch)
LLY : 966.99 (+1.95%)
Are CNTA, KORE, CWAN Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

KORE : 9.16 (+0.11%)
CNTA : 39.59 (unch)
CWAN : 24.38 (+0.12%)
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

KZR : 7.29 (-0.95%)
CNTA : 39.59 (unch)
APLS : 41.02 (-0.02%)
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--KZR, CNTA, AFBI, and APLS

NEW YORK , April 8, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of...

AFBI : 22.48 (+0.09%)
KZR : 7.29 (-0.95%)
CNTA : 39.59 (unch)
APLS : 41.02 (-0.02%)
Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

KORE : 9.16 (+0.11%)
CNTA : 39.59 (unch)
APLS : 41.02 (-0.02%)
The Next Big AI Winner Might Not Be a Tech Company

Lilly’s AI push shows how non-tech firms can dominate the next wave.

NVDA : 219.44 (+1.97%)
$SPX : 7,412.84 (+0.19%)
CNTA : 39.59 (unch)
LLY : 966.99 (+1.95%)
Lilly's Next Empire: A $10 Billion Bet on AI and Neuroscience

Eli Lilly is securing its future by investing in AI drug discovery and expanding its pipeline into the multi-billion-dollar neuroscience market.

CNTA : 39.59 (unch)
LLY : 966.99 (+1.95%)
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Centessa Pharmaceuticals plc (NASDAQ: CNTA)

NEW YORK , April 1, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions...

CNTA : 39.59 (unch)
Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Centessa Pharmaceuticals...

CNTA : 39.59 (unch)
LLY : 966.99 (+1.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Centessa Pharmaceuticals plc is a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients. Centessa Pharmaceuticals plc is based in Cambridge, United Kingdom.

See More

Key Turning Points

3rd Resistance Point 39.74
2nd Resistance Point 39.69
1st Resistance Point 39.64
Last Price 39.59
1st Support Level 39.54
2nd Support Level 39.50
3rd Support Level 39.45

See More

52-Week High 40.26
Last Price 39.59
Fibonacci 61.8% 29.06
Fibonacci 50% 25.60
Fibonacci 38.2% 22.15
52-Week Low 10.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.